Kolmar Korea

한국콜마 · 161890

Materials Chemicals · KOSPI

Small-cap

Market cap US$1.4B (₩2T)

Overview

Kolmar Korea develops and manufactures cosmetics, including skincare, functional, and colour products, as well as prescription pharmaceuticals, health and wellness products, and cosmetic packaging, supplying brand owners who place orders under their own labels.

Listed on KOSPI, Korea's main stock exchange, it serves cosmetics brands, pharmaceutical companies, and retailers across domestic and international markets. The vast majority of its cosmetics revenue comes from an ODM (original development and design manufacturing) model, meaning it owns the formulation technology itself rather than simply following a client's recipe.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$2B
▲ +11.0% YoY
Operating profit · FY2025
US$173.6M
▲ +23.6% YoY
Net income · FY2025
US$121.9M
▲ +34.2% YoY

Revenue

  • FY2023US$1.6B
  • FY2024US$1.8B
  • FY2025US$2B

Operating profit

  • FY2023US$98.7M
  • FY2024US$140.5M
  • FY2025US$173.6M

Net income

  • FY2023US$18.2M
  • FY2024US$90.8M
  • FY2025US$121.9M

Key ratios (FY2025)

ROE
10.1%
Debt/Eq
107.4%
Op. margin
8.8%
Net margin
6.2%
Rev. YoY
▲ +11.0%

Why it matters

Kolmar Korea was spun off from the original 한국콜마㈜ and now operates as a holding-style group with subsidiaries spanning cosmetics, packaging, and pharmaceuticals across Korea, China, and North America.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.